United States. Food and Drug Administration
Endologix, Inc., a company specializing in minimally invasive treatments for vascular diseases, has received approval from the U.S. Food and Drug Administration (FDA) to enroll patients in a clinical trial utilizing the Powerlink System to treat abdominal aortic aneurysm (AAA) in patients with large diameter aortic necks. The Powerlink
Pharmaceutical industry
The SYNTAX clinical trial, initiated by Boston Scientific Corporation in partnership with Angiotech Pharmaceuticals, Inc., aims to investigate the effectiveness of drug-eluting stents versus cardiac surgery in treating patients with complex coronary artery disease. The trial, which began enrolling patients in April, will involve over 4,200 patients across 90
Pharmaceutical industry
The SYNTAX clinical trial, a multicenter, prospective trial, has begun enrolling patients with complex coronary artery disease in Europe and the United States. The trial compares the performance of drug-eluting stents with cardiac surgery in patients with disease in all three coronary arteries, the left main coronary artery, or both.
Drugs
Eli Lilly and Co. has taken a substantial step towards advancing cancer research by committing $12.5 million to the Damon Runyon Cancer Research Foundation. This significant contribution aims to accelerate the pace and progress of cancer research in the United States. According to an American Cancer Society report, cancer
Drugs
Patients with chronic hepatitis C who are naive to interferon-alpha treatments showed significant antiviral activity and were well-tolerated to Albuferon, a new treatment option in development by Human Genome Sciences, Inc. (HGSI). The phase II clinical trial, presented at the 40th Annual Meeting of the European Association for the Study
Pharmaceutical industry
AnorMED, a biopharmaceutical company, has received a response from the U.S. Food and Drug Administration (FDA) regarding its Special Protocol Assessment (SPA) for two pivotal phase III clinical trials of AMD3100, a potential new stem cell mobilizing agent for stem cell transplantation in cancer patients. The FDA's
Pharmaceutical industry
Results from a phase 1 clinical trial with CG53135 have shown that the drug is well-tolerated and supports the company's strategy to investigate its safety and efficacy in preventing oral mucositis (OM) in patients undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT). The trial, presented at
